Edition:
India

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

12.37USD
17 Sep 2019
Change (% chg)

$0.18 (+1.48%)
Prev Close
$12.19
Open
$12.06
Day's High
$12.37
Day's Low
$12.06
Volume
4,739
Avg. Vol
277,051
52-wk High
$16.59
52-wk Low
$5.14

Latest Key Developments (Source: Significant Developments)

Epizyme Reports Updated Data From Phase 2 Trial Of Tazemetostat
Friday, 21 Jun 2019 

June 21 (Reuters) - Epizyme Inc ::EPIZYME REPORTS UPDATED DATA FROM PHASE 2 TRIAL OF TAZEMETOSTAT IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.EPIZYME INC - TAZEMETOSTAT NDA SUBMISSION FOR FOLLICULAR LYMPHOMA ON TRACK FOR Q4 2019.EPIZYME INC - DURABLE AND CLINICALLY MEANINGFUL RESPONSES OBSERVED IN FOLLICULAR LYMPHOMA PATIENTS REGARDLESS OF EZH2 MUTATIONAL STATUS.EPIZYME INC - TAZEMETOSTAT WAS GENERALLY WELL TOLERATED IN BOTH PATIENTS WITH EZH2 ACTIVATING MUTATIONS AND THOSE WITH WILD-TYPE EZH2..EPIZYME INC - TAZEMETOSTAT NDA SUBMISSION FOR FOLLICULAR LYMPHOMA ON TRACK FOR Q4 2019.  Full Article

Epizyme Q4 Loss Per Share $0.29
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Epizyme Inc ::EPIZYME PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.29.Q4 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.OPERATING RUNWAY INTO Q2 OF 2020.TWO SUCCESSIVE TAZEMETOSTAT NDA SUBMISSIONS FOR EPITHELIOID SARCOMA AND FOLLICULAR LYMPHOMA ON TRACK FOR 2019.EPIZYME - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $240.3 MILLION AS OF DEC 31, 2018, VERSUS $276.4 MILLION AS OF DEC 31, 2017.  Full Article

Epizyme Announces Registration Path for Tazemetostat for Follicular Lymphoma
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Epizyme Inc ::EPIZYME ANNOUNCES REGISTRATION PATH FOR TAZEMETOSTAT FOR FOLLICULAR LYMPHOMA AND PROVIDES PIPELINE UPDATES AND 2019 GUIDANCE.EPIZYME - PATH DEFINED TO SUBMIT FOR ACCELERATED APPROVAL IN ALL FL PATIENTS AFTER AT LEAST 2 PRIOR LINES OF THERAPY BASED ON FULLY ENROLLED PHASE 2 STUDY.EPIZYME INC - OPERATING RUNWAY EXTENDED INTO Q2 OF 2020.EPIZYME - RECENTLY CONDUCTED MEETING WITH FDA TO DISCUSS FL REGISTRATION STRATEGY BASED ON CURRENT PATIENT POPULATION IN ONGOING PHASE 2 CLINICAL TRIAL.EPIZYME - FOLLOWING FDA DISCUSSION, CO DEFINED REGISTRATION STRATEGY FOR TAZEMETOSTAT IN BOTH EZH2 MUTANT AND WILD TYPE FL PATIENT POPULATIONS.EPIZYME - ANTICIPATES SUBMITTING NEW DRUG APPLICATION FOR NEW INDICATION FOR TAZEMETOSTAT IN Q4 OF 2019.  Full Article

Epizyme Reports Q1 Loss Per Share Of $0.49
Tuesday, 8 May 2018 

May 8 (Reuters) - Epizyme Inc ::EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q1 LOSS PER SHARE $0.49.Q1 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.EPIZYME - CONTINUES TO EXPECT EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AS OF MARCH 31 TO BE SUFFICIENT TO FUND OPERATIONS INTO Q3 2019.  Full Article

Epizyme Q4 Loss Per Share $0.52
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Epizyme Inc ::EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES.Q4 LOSS PER SHARE $0.52.Q4 EARNINGS PER SHARE VIEW $-0.57 -- THOMSON REUTERS I/B/E/S.EPIZYME - SEES EXISTING CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DEC 31, 2017 TO BE SUFFICIENT TO FUND OPERATIONS INTO Q3 2019.  Full Article

Epizyme says ‍no revenue recognized in Q3 of 2017 compared to $6.6 mln for Q3 of 2016​
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Epizyme Inc :Epizyme reports third quarter 2017 operating results and company updates.Epizyme Inc - ‍no revenue recognized in q3 of 2017, compared to $6.6 million for q3 of 2016​.Epizyme Inc - ‍research and development (research and development) expenses were $28.7 million for q3 of 2017, compared to $23.9 million​.Epizyme Inc - ‍existing cash, cash equivalents and marketable securities as of sept 30 will be sufficient to fund planned operations into at least q3 2019​.  Full Article